Literature DB >> 952262

Effect of amiodarone in the Wolff-Parkinson-White syndrome.

H J Wellens, K I Lie, F W Bär, J C Wesdorp, H J Dohmen, D R Düren, D Durrer.   

Abstract

The effect of amiodarone in the Wolff-Parkinson-White syndrome was studied with programmed electrical stimulation of the heart in 15 patients. All 15 patients had circus movement tachycardias; 7 also had atrial fibrillation. Programmed electrical stimulation was performed before and after 14 days of oral administration of amiodarone. The effective refractory period of the accessory pathway lengthened in an atrioventricular direction in all patients and in a ventriculoatrial direction in eight patients. The effective refractory period of the atrium and ventricle lengthened in 14 and 12 patients, respectively. After administration of amiodarone, circus movement tachycardia could no longer be initiated in five patients. The zone of tachycardia narrowed in four patients, did not change in two and increased in seven. The effect of amiodarone on initiation of circus movement tachycardia could be related to differences in effect of the drug and in the mechanism of tachycardia in individual patients. In all patients in whom tachycardias could still be initiated after treatment with amiodarone the heart rate during tachycardia was slower than before treatment. This slowing was caused by a decrease in conduction velocity of the circulatory wave in different parts of the tachycardia circuit. The effect of amiodarone in prolonging the refractory period of the accessory pathway makes this drug especially useful in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 952262     DOI: 10.1016/0002-9149(76)90148-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  [Drug therapy of tachyarrhythmias (author's transl)].

Authors:  K Theisen
Journal:  Klin Wochenschr       Date:  1978-02-15

Review 2.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

3.  Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias.

Authors:  P J Wheeler; R Puritz; D V Ingram; D A Chamberlain
Journal:  Postgrad Med J       Date:  1979-01       Impact factor: 2.401

Review 4.  Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.

Authors:  K A Muhiddin; P Turner
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

Review 5.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

6.  Electrophysiological effects of lorcainide, a new antiarrhythmic drug. Observations in patients with and without pre-excitation.

Authors:  F W Bär; J Farré; D Ross; E J Vanagt; A P Gorgels; H J Wellens
Journal:  Br Heart J       Date:  1981-03

7.  Acceleration of the ventricular response to atrial flutter by amiodarone in an infant with Wolff-Parkinson-White syndrome.

Authors:  J A Till; M Baxendall; A Benetar
Journal:  Br Heart J       Date:  1993-07

8.  Acute effects of amiodarone upon the canine sinus node and atrioventricular junctional region.

Authors:  H O Gloor; F Urthaler; T N James
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Electrophysiological effects of sotalol--just another beta blocker?

Authors:  A W Nathan; K J Hellestrand; R S Bexton; D E Ward; R A Spurrell; A J Camm
Journal:  Br Heart J       Date:  1982-06

10.  Amiodarone pneumonitis: three further cases with a review of published reports.

Authors:  J I Darmanata; N van Zandwijk; D R Düren; E A van Royen; W J Mooi; T A Plomp; H M Jansen; D Durrer
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.